Our studies have shown that in the experimental diabetes, the lymph nodes are broken along with the blood vessel drainage disorder. All this ultimately leads to the accumulation of tissue-exchange toxic products in tissues that weaken tissue lymphadraining properties and the development of various complications resulting from diabetes. From the literature data it is clear that the use of the body in the treatment of diabetes does not only have a beneficial effect on hemostasis but also improves microcirculation and facilitates the progression of diabetes.
Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care 2014;2:20 doi:10.1186/2052-0492-2-20
Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. Intern Emerg Med 2013;8:23–32.
Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586–92.
Wada H, Asakura H, Okamoto K et al. Japanese Society of Thrombosis Hemostasis/DIC Subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010;125:6–11.
Nakagawa M. An investigation report concerning incidence and underlying cause of DIC in Japan: a study report by the research committee on blood coagulation on abnormalities in 1998. Special diseases designated by Japanese Ministry of Health and Welfare, 1999:157–64. Japanese.
Dhainaut JF, Yan SB, Joyce DE et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2:1924–33.
D et al. Japanese Association for Acute Medicine Sepsis Registry (JAAMSR) Study Group. Epidemiology of severe sepsis in Japanese intensive care units: a prospective multicenter study. J Infect Chemother 2014;20:157–62.
Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010;7:260–73.